Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib-Reference-Cited by-同舟云学术

Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib

Author:

Yamamoto Naoki¹²,Yamasaki Takahiro¹³,Takami Taro¹,Uchida Koichi⁴,Fujisawa Koichi¹⁵,Matsumoto Toshihiko¹³,Saeki Issei¹,Terai Shuji⁶,Sakaida Isao¹

Affiliation:

1. Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine

2. Yamaguchi University Health Administration Center

3. Department of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine

4. Department of Human Nutrition Faculty of Nursing and Human Nutrition, Yamaguchi Prefectural University

5. Center of Research and Education for Regenerative Medicine, Yamaguchi University Graduate School of Medicine

6. Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University

Publisher

The Society for Free Radical Research Japan

Subject

Clinical Biochemistry,Nutrition and Dietetics,Medicine (miscellaneous)

Link

Reference35 articles.

1. 1 GLOBOCAN 2012. http://globocan.iarc.fr/Default.aspx.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

4. Effects of Iron Chelation in Osteosarcoma;Current Cancer Drug Targets;2020-12-30